loader image
Thursday, January 8, 2026
71.3 F
McAllen
- Advertisement -

Researchers identify markers that could detect pregnancy risks earlier than currently available tests

Translate to Spanish or other 102 languages!

“Our group has had a long-term interest in developing screening tests to identify pregnant women early in pregnancy who are at risk of pregnancy complications,” says Professor Roberts, who leads the PHaB Lab. Image for illustration purposes.

Mega Doctor News

- Advertisement -

By Taylor & Francis

Newswise — Researchers from Flinders University and the Robinson Research Institute at the University of Adelaide have identified distinctive biological markers that could improve the routine blood tests pregnant women already undergo and detect risks for pregnancy complications earlier than currently possible.

Published in the journal RNA Biology, the study looked at unique genetic codes in the placenta, called microRNAs, found in the blood of pregnant women, to identify specific biomarkers that could indicate different pregnancy risks.

- Advertisement -

The research was led by Ms Melanie Smith and Professor Claire Roberts from the Pregnancy Health and Beyond (PHaB) Laboratory based at Flinders University.

“Our group has had a long-term interest in developing screening tests to identify pregnant women early in pregnancy who are at risk of pregnancy complications,” says Professor Roberts, who leads the PHaB Lab.

“The earlier we can identify those at risk the earlier we can implement extra clinical monitoring and prevention strategies.”

A healthy placenta is crucial to the health of a pregnancy and this has implications for the long term health of both the mother and the baby.

- Advertisement -

The team set out to profile placental microRNAs in the placenta and maternal blood in early to mid-pregnancy.

“We need to know what microRNAs are present in healthy pregnancies and identify those that could indicate whether the placenta is functioning well or not. These could then be used to identify pregnancies at risk,” says lead author Melanie Smith, who completed the research while at the Robinson Research Institute, University of Adelaide.

“We have found that placental microRNAs present in maternal blood can be used to determine whether or not the placenta is receiving adequate oxygen from the mother.

“We also found that the amount of a cluster of microRNAs from Chromosome 19, which are only made by the placenta and are present in maternal blood, change in response to the initiation of maternal blood flow into the placenta after 10 weeks of gestation.”

“Our data suggests it is possible from a simple blood test from the mother to identify babies who may not be getting enough oxygen in the womb via the placenta and would benefit from extra clinical monitoring.”

Most women will have routine blood tests as part of their obstetric care, with the researchers highlighting they pose very little risk to the ongoing pregnancy.

“Our research could pave the way for a significant improvement in these screening tools, allowing assessment of placental health, and therefore fetal health, in real time throughout pregnancy.”

The research team will now turn to the development of the test.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Historic Reset of U.S. Nutrition Policy with New Food Pyramid

Mega Doctor News WASHINGTON, D.C. – U.S. Department of Health and Human Services...

Metabolic Trigger Identified That Shuts Down Key Tumor‑Fighting Gene

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to researchers from The University of Texas MD Anderson Cancer Center. 

No-Cost COVID-19 Testing Ends January 31st

The Hidalgo County Health & Human Services Department announces that no-cost COVID-19 testing at the Hidalgo County Public Health Laboratory will conclude on January 31, 2026.

MD Anderson Partners with SOPHiA GENETICS to Accelerate Innovation in AI Precision Oncology

The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites SOPHiA GENETICS’ AI-powered analytics with MD Anderson’s clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.
- Advertisement -
×